{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:26:32Z","timestamp":1769109992899,"version":"3.49.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jsat.2020.108263","type":"journal-article","created":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T19:00:24Z","timestamp":1609009224000},"page":"108263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder"],"prefix":"10.1016","volume":"123","author":[{"given":"Kristi Lynn","family":"Stringer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten J.","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2020.108263_bb0005","author":"American Society of Addiction Medicine. Adjusting drug testing protocols"},{"issue":"2","key":"10.1016\/j.jsat.2020.108263_bb0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/08897077.2018.1443541","article-title":"Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program","volume":"39","author":"Bachhuber","year":"2018","journal-title":"Substance Abuse"},{"issue":"1","key":"10.1016\/j.jsat.2020.108263_bb0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13011-020-0252-z","article-title":"Routes of non-traditional entry into buprenorphine treatment programs","volume":"15","author":"Champagne-Langabeer","year":"2020","journal-title":"Substance Abuse Treatment and Prevention Policy"},{"issue":"10173","key":"10.1016\/j.jsat.2020.108263_bb0020","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.jsat.2020.108263_bb0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jsat.2013.11.002","article-title":"Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals","volume":"46","author":"Hall","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2 Suppl","key":"10.1016\/j.jsat.2020.108263_bb0030","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","article-title":"From morphine clinics to buprenorphine: Regulating opioid agonist treatment of addiction in the United States","volume":"70","author":"Jaffe","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.jsat.2020.108263_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment","volume":"14","author":"Jakubowski","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2020.108263_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.05.002","article-title":"Expanding low- threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap","volume":"103","author":"Krawczyk","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.jsat.2020.108263_bb0045","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world","volume":"8","author":"Lofwall","year":"2014","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2020.108263_bb0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2019.03.009","article-title":"Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program","volume":"200","author":"Payne","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2020.108263_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.09.003","article-title":"Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: A qualitative study of a bridge clinic","volume":"107","author":"Snow","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.jsat.2020.108263_bb0060","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2105\/AJPH.2019.305525","article-title":"Retention of patients with multiple vulnerabilities in a federally qualified health center buprenorphine program: Pennsylvania, 2017\u20132018","volume":"110","author":"Weinstein","year":"2010","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.jsat.2020.108263_bb0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"Journal of Substance Abuse Treatment"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547220305201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547220305201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:52:42Z","timestamp":1760039562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547220305201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":13,"alternative-id":["S0740547220305201"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108263","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108263"}}